MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$9.24 – $9.70
Volume16,026
Market cap$48M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$48M
Price / earnings
—
Price / book
-2.95×
Price / sales
240×
EV / sales
202.64×
EV / EBITDA
-3.59×
Profitability
Earnings per share
-$2.15
Return on assets
-133.75%
Return on equity
67.84%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
0.97×
Quick ratio
0.97×
Cash ratio
0.91×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.22M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INKT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$200K
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$200K
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.03M
$1.33M
$1.68M
$1.76M
$1.85M
$1.85M
$1.27M
$808.9K
Research and development
$1.8M
$1.89M
$1.2M
$1.51M
$1.14M
$1.84M
$1.26M
$1.41M
Total operating expenses
$2.84M
$3.22M
$2.88M
$2.71M
$3.18M
$4.05M
$2.7M
$2.5M
Operating income
-$2.64M
-$3.22M
-$2.88M
-$2.71M
-$3.18M
-$4.05M
-$2.7M
-$2.5M
Interest expense
$0
$0
$0
$111.23K
$0
$0
$0
$39.57K
Income before taxes
-$2.55M
-$3.13M
-$2.74M
-$2.6M
-$2.89M
-$4.24M
-$2.77M
-$2.46M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.55M
-$3.13M
-$2.74M
-$2.6M
-$2.89M
-$4.24M
-$2.77M
-$2.46M
Net income attributable to common shareholders
-$2.55M
-$3.13M
-$2.74M
-$2.6M
-$2.89M
-$4.24M
-$2.77M
-$2.46M
EBITDA
-$2.6M
-$3.18M
-$2.85M
-$2.67M
-$3.14M
-$4M
-$2.65M
-$2.45M
Basic earnings per share
-$0.50
-$0.62
-$0.57
-$0.55
-$0.65
-$1.06
-$0.70
-$0.62
Diluted earnings per share
-$0.50
-$0.62
-$0.57
-$0.55
-$0.65
-$1.06
-$0.70
-$0.62
Recent news
Company coverage with links to the original publishers.
MiNK Therapeutics reported a Q3 loss of $0.5 per share, beating consensus estimates of $0.66 loss by 24.24%. The company posted $0.2 million in revenues, surpassing estimates by 33.33% compared to zero revenues a year ago. However, shares have underperformed the market, down 10.2% year-to-date versus the S&P 500's 9.9% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.
MiNK Therapeutics announced Phase II trial results for agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer. The study achieved a 77% disease control rate with long-term survival beyond 20 months in a subset of patients. An induction treatment strategy showed significant improvements in progression-free survival (6.9 vs. 3.5 months) and overall survival (9.5 vs. 5.2 months), though the trial did not meet its primary endpoint of objective response rate.
MiNK Therapeutics announced that Phase II trial data from Memorial Sloan Kettering Cancer Center evaluating agenT-797 (an allogeneic iNKT cell therapy) combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer will be presented at AACR 2026. The study represents one of the first clinical evaluations of iNKT cell therapy combined with dual checkpoint modulation in this indication, addressing an area of high unmet medical need.
MiNK Therapeutics presented translational data at Keystone Symposia demonstrating significant depletion of iNKT cells in lung tissue from advanced IPF patients, supporting the mechanistic rationale for iNKT cell replenishment as a potential therapeutic approach. The findings expand MiNK's iNKT platform into chronic fibrotic lung disease, addressing a large unmet medical need affecting approximately 100,000 U.S. patients with limited treatment options.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.